Bayer urged to restart compassionate use program of Kogenate

Published: 2011-07-29 06:58:00

Updated: 2011-07-29 06:58:00

A local hemophiliac group has called for Bayer to re-initiate their compassionate use program of Kogenate FS, antihemophilic factor (recombinant) for 21 Korean patients.

Kogenate is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-opera...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK